Robert  Veltri, Ph.D.
Robert Veltri, Ph.D.

Associate Professor of Urology
Johns Hopkins Medical Institutions

The Brady Urological Research Institute, Park Building, 213, 600 North Wolfe Street , Baltimore, MD 21287-2101

Appointments: (410) 955-6380


Fax: (410) 502-7711

Dr. Veltri has 25 years of academic and 20 years of commercial experience in the area of in vitro diagnostics, therapeutic drug development and cancer biomarkers. He uses advanced technology for discovery, qualification, and validation.

Robert W. Veltri, Ph.D. joined Johns Hopkins Medical Institutions (JHMI) in January, 2002 and is currently Associate Professor of Urology and Oncology at and studies the biomarkers for prostate and bladder cancer ( ). 

Currently, Dr. Veltri has collaborations with Case Western Reserve University biomedical engineering department and they are studying differentiating indolent vs. aggressive prostate cancer (PCa).  He is currently collaborating with PharmaSeq Inc. to develop microtransponder-based (p-Chip) immunoassays to detect serum or urine biomarkers.

PharmaSeq and Dr. Veltri currently have a Phase II SBIR sub contract to develop a multiplex serum assay for prostate cancer using P-chip multitransponders.

He also has grants that include: Early Detection Research Network (EDRN) to characterize indolent vs. aggressive PCa; and two DOD grants one related to research on Active Surveillance monitoring in PCa and a second on Cancer Testes Antigens as biomarkers for aggressive PCa.

Career experiences:

  1. Dr. Veltri also served as Professor & Director of Otolaryngic Research and a member of the faculty of microbiology, surgery from 1968-80;
  2. He managed R&D at a diagnostic company (1980-84), where he developed rapid FDA approved In Vitro diagnostic devices;
  3. In 1985, he co-founded a therapeutics company (Theracel), which created nine patents covering several Aldol and Michael addition derivatives of Vitamin C;
  4. at UroCor his R&D team (1991-2001) developed several products including UroScore, a urinalysis Stones 24-hour product, and a novel bladder cancer assay for p53 gene mutations, and the DD-23 BlCa detection urine biomarker and his R&D group patented several genes involved in PCa.

Dr. Veltri has authored over 162 scientific publications and is either inventor or co-inventor on twenty-three patents and two trademarks.